Liangyou Gu1, Hongzhao Li1, Hanfeng Wang1, Xin Ma1, Lei Wang1, Luyao Chen1, Wenlei Zhao2, Yu Zhang1, Xu Zhang3. 1. Department of Urology/State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/PLA Medical School, Beijing, 100853, China. 2. School of Medicine, Nankai University, Tianjin, China. 3. Department of Urology/State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/PLA Medical School, Beijing, 100853, China. xzhang@tjh.tjmu.edu.cn.
Abstract
PURPOSE: To assess the prognostic significance of sarcomatoid differentiation for surgically treated metastatic renal cell carcinoma (mRCC). METHODS: Patients undergoing cytoreductive nephrectomy for mRCC in our center between 2006 and 2014 were included. All enrolled patients were separated into two groups according to the presence of sarcomatoid differentiation. Clinical and pathological variables were recorded. Student's t test or Chi-square test was applied to compare them. Univariate and multivariate Cox regression were performed to determine independent prognostic factors for oncologic outcomes. RESULTS: Of the 184 patients with mRCC included, 27 (14.7%) patients presented with sarcomatoid differentiation. The presence of sarcomatoid differentiation was associated with higher rates of non-clear cell histology (P = 0.009), higher Fuhrman grade (P < 0.001), higher rates of presenting tumor necrosis (P = 0.005), worse IMDC risk group (P = 0.022), and MSKCC risk group (P = 0.020). Patients with sarcomatoid differentiation showed shorter median progression-free survival and overall survival. Multivariate analysis identified that sarcomatoid differentiation was independently associated with progression-free survival (hazard ratio [HR]: 2.002, 95% CI 1.047-3.828; P = 0.036) and overall survival (HR: 1.922, 95% CI 1.073-3.445; P = 0.028). Sarcomatoid differentiation remained to be independently associated with inferior PFS (HR: 2.097, 95% CI 1.091-4.030; P = 0.026) and OS (HR: 2.245, 95% CI 1.276-3.951; P = 0.005) for clear cell mRCC. CONCLUSION: The presence of sarcomatoid differentiation is independently associated with poor oncologic outcomes for surgically treated mRCC patients. The association remains significant when the subject of study is restricted to clear cell mRCC.
PURPOSE: To assess the prognostic significance of sarcomatoid differentiation for surgically treated metastatic renal cell carcinoma (mRCC). METHODS:Patients undergoing cytoreductive nephrectomy for mRCC in our center between 2006 and 2014 were included. All enrolled patients were separated into two groups according to the presence of sarcomatoid differentiation. Clinical and pathological variables were recorded. Student's t test or Chi-square test was applied to compare them. Univariate and multivariate Cox regression were performed to determine independent prognostic factors for oncologic outcomes. RESULTS: Of the 184 patients with mRCC included, 27 (14.7%) patients presented with sarcomatoid differentiation. The presence of sarcomatoid differentiation was associated with higher rates of non-clear cell histology (P = 0.009), higher Fuhrman grade (P < 0.001), higher rates of presenting tumor necrosis (P = 0.005), worse IMDC risk group (P = 0.022), and MSKCC risk group (P = 0.020). Patients with sarcomatoid differentiation showed shorter median progression-free survival and overall survival. Multivariate analysis identified that sarcomatoid differentiation was independently associated with progression-free survival (hazard ratio [HR]: 2.002, 95% CI 1.047-3.828; P = 0.036) and overall survival (HR: 1.922, 95% CI 1.073-3.445; P = 0.028). Sarcomatoid differentiation remained to be independently associated with inferior PFS (HR: 2.097, 95% CI 1.091-4.030; P = 0.026) and OS (HR: 2.245, 95% CI 1.276-3.951; P = 0.005) for clear cell mRCC. CONCLUSION: The presence of sarcomatoid differentiation is independently associated with poor oncologic outcomes for surgically treated mRCC patients. The association remains significant when the subject of study is restricted to clear cell mRCC.
Authors: Badar M Mian; Nishin Bhadkamkar; Joel W Slaton; Peter W T Pisters; Danai Daliani; David A Swanson; Louis L Pisters Journal: J Urol Date: 2002-01 Impact factor: 7.450
Authors: M de Peralta-Venturina; H Moch; M Amin; P Tamboli; S Hailemariam; M Mihatsch; J Javidan; H Stricker; J Y Ro; M B Amin Journal: Am J Surg Pathol Date: 2001-03 Impact factor: 6.394
Authors: Mark Bi; Siming Zhao; Jonathan W Said; Maria J Merino; Adebowale J Adeniran; Zuoquan Xie; Cayce B Nawaf; Jaehyuk Choi; Arie S Belldegrun; Allan J Pantuck; Harriet M Kluger; Kaya Bilgüvar; Richard P Lifton; Brian Shuch Journal: Proc Natl Acad Sci U S A Date: 2016-02-10 Impact factor: 11.205
Authors: Naomi B Haas; Xinyi Lin; Judith Manola; Michael Pins; Glenn Liu; David McDermott; David Nanus; Elisabeth Heath; George Wilding; Janice Dutcher Journal: Med Oncol Date: 2011-02-06 Impact factor: 3.064
Authors: Kirk A Keegan; Clayton W Schupp; Karim Chamie; Nicholas J Hellenthal; Christopher P Evans; Theresa M Koppie Journal: J Urol Date: 2012-06-13 Impact factor: 7.450
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri Journal: Lancet Oncol Date: 2013-01-09 Impact factor: 41.316
Authors: Robert J Motzer; Jennifer Bacik; Lawrence H Schwartz; Victor Reuter; Paul Russo; Stephanie Marion; Madhu Mazumdar Journal: J Clin Oncol Date: 2004-02-01 Impact factor: 44.544
Authors: Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki Journal: World J Urol Date: 2018-06-01 Impact factor: 4.226
Authors: Ross J Mason; Lori Wood; Anil Kapoor; Naveen Basappa; George Bjarnason; Stephen A Boorjian; Rodney H Breau; Ilias Cagiannos; Michael A S Jewett; Pierre I Karakiewicz; Wassim Kassouf; Christian Kollmannsberger; Aly-Khan A Lalani; Jean-Baptiste Lattouf; Luke T Lavallée; Stephen Pautler; Nicholas Power; Patrick Richard; Alan So; Simon Tanguay; Ricardo A Rendon Journal: Can Urol Assoc J Date: 2019-06 Impact factor: 1.862
Authors: Andrew W Silagy; Roy Mano; Kyle A Blum; Renzo G DiNatale; Julian Marcon; Satish K Tickoo; Eduard Reznik; Jonathan A Coleman; Paul Russo; A Ari Hakimi Journal: Urology Date: 2019-11-11 Impact factor: 2.649
Authors: Renzo G DiNatale; Wanling Xie; Maria F Becerra; Andrew W Silagy; Kyrollis Attalla; Alejandro Sanchez; Roy Mano; Julian Marcon; Kyle A Blum; Nicole E Benfante; Martin H Voss; Robert J Motzer; Jonathan Coleman; Toni K Choueiri; Ed Reznik; Paul Russo; Daniel Y C Heng; A Ari Hakimi Journal: Eur Urol Oncol Date: 2019-11-14
Authors: Jose A Karam; A Ari Hakimi; Kyle A Blum; Sounak Gupta; Satish K Tickoo; Timothy A Chan; Paul Russo; Robert J Motzer Journal: Nat Rev Urol Date: 2020-10-13 Impact factor: 14.432